

A COMPREHENSIVE REVIEW ON “THE MULTIFACETED WORLD OF MONOCLONAL ANTIBODIES: A DETAILED EXPLORATION OF THEIR MECHANISMS, ENGINEERING STRATEGIES, APPLICATIONS, AND FUTURE PROSPECTS”

Sakshi Sharma^{1*}, Salil Sanghvi¹, Mangal S. Panwar¹

Gyanodaya Institute Of Pharmacy , Gyanodaya University , Neemuch (M.P.) 458441.

Abstract: Monoclonal antibodies are lab made proteins designed to function like a normal antibodies. Monoclonal antibodies (mAb) have revolutionized medicine by providing targeted and personalized means of disease treatment. The mAb has found its way into the clinic for the treatment of cancer, autoimmune disorders, infectious diseases, and inflammatory conditions. Their specific recognition and inactivation of disease targets has not only enhanced curative effects but also minimized off-target effects relative to traditional drugs. There are still challenges to overcome, however, such as high costs of manufacturing, immunogenicity, and delivery restrictions. In the future, advancements in genetic engineering and biotechnology hold the promise to make them safer, more effective, and cost-effective. This review captures the present status of monoclonal antibodies and offers a perspective on their future role in designing next-generation therapies.

Keywords: *Monoclonal antibodies (mAbs), Future prospective, Therapeutic applications, Immunotherapy, Hybridoma technology.*

INTRODUCTION

Monoclonal antibodies (mAbs) are in-vitro-produced molecules designed to mimic the body's defense response against dangerous pathogens like viruses and bacteria. They are identical, homogeneous immunoglobulins obtained from one clone of B lymphocytes that recognize one epitope on the surface antigen and specifically bind.

In contrast to the heterogeneous and multi-epitope-specific polyclonal antibodies, monoclonal antibodies are homogenous, uniform, and strongly reproducible-making them perfect subjects for therapeutic applications.

Advantages of using mAb

- Though expensive, monoclonal antibodies are cheaper to develop than conventional drugs because it is based on tested technology.

- Side effects can be treated and reduced by using mice-human hybrid cells or by using fraction of antibodies.
- They bind to specific diseased or damaged cells needing treatment.
- They treat a wide range of conditions.

Disadvantages of using mAb

- Time consuming project- anywhere between 6-9 months.
- Very expensive and needs considerable effort to produce them.
- Small peptide and fragment antigens may not be good antigen- mAb may not recognize the original antigen.
- Hybridoma culture may be subject to contamination.
- System is only well developed for limited animal and not for other animals.

DISCOVERY OF MONOCLONAL ANTIBODIES

The notion of antibody specificity began way back with Emil von Behring and Shiba saburo Kitasato in the 1890s, who showed the protective efficacy of serum antibodies in treating diphtheria.

Yet, the breakthrough moment occurred in 1975, with Georges Köhler and César Milstein inventing the hybridoma technology enabling the mass production of antibodies that have identical specificity and high purity.

This led to them being awarded the 1984 Nobel Prize in Physiology or Medicine and the setting up of the contemporary monoclonal antibody sector. In 1986, first monoclonal antibody was licensed by FDA.

Orthoclone OKT3 (muromonab-CD3) which was approved for use in preventing kidney transplant rejection.

Landmarks in Monoclonal Antibody Research

Early Discoveries: Antibody Basics (1890–1940s)

1890 – Discovery of Antibodies: Emil von Behring and Shiba saburo Kitasato discovered antitoxins (early antibodies) that could neutralize diphtheria and tetanus toxins. This was the first proof that the body produces specific immune factors — the foundation of immunology [1].

1930s–1940s – Antibody Diversity Concept: Scientists realized antibodies are proteins produced by B cells, but their exact structure and diversity were still unclear.

Structural Understanding (1950s–1960s)

1959 – Antibody Structure Elucidated: Gerald Edelman and Rodney Porter independently determined the Y-shaped structure of antibodies, earning them the 1972 Nobel Prize. They revealed heavy and light chains,

variable and constant regions, crucial for understanding specificity.

Birth of Monoclonal Antibody Technology (1970s)

1975-Hybridoma Technique (Major Breakthrough)

- *Georges Köhler and César Milstein* developed the hybridoma technique at the MRC Laboratory in Cambridge, UK.
- By fusing a B cell (producing a specific antibody) with a myeloma cell (cancerous, immortal cell line), they created hybridoma capable of producing identical (monoclonal) antibodies indefinitely.
- This invention revolutionized biomedical research and won the 1984 Nobel Prize in Physiology or Medicine.

Late 1970s-First Experimental Uses

- Researchers began producing monoclonal antibodies for diagnostics and research tools (e.g., identifying cell markers).

Therapeutic Applications Begin (1980s–1990s)

1986 – First FDA-Approved Monoclonal Antibody Drug

- Muromonab-CD3 (OKT3) became the first mAb approved for clinical use.
- It was a murine (mouse-derived) antibody used to prevent kidney transplant rejection.
- However, it triggered strong immune reactions because of its non-human origin.

1990s – Engineering Advances

- Development of chimeric, humanized, and fully human antibodies to reduce immunogenicity:
 - *Chimeric antibodies* (~65% human): e.g., Rituximab (anti-CD20, 1997)
 - *Humanized antibodies* (~95% human): e.g., Trastuzumab (Herceptin, 1998)
 - *Fully human antibodies* (100% human): e.g., Adalimumab (Humira, 2002)




Figure: Therapeutic Applications of Monoclonal Antibodies

Molecular and Genetic Engineering Era (2000s–2010s)

Phage Display Technology (1990s–2000s)

- *George P. Smith and Sir Gregory Winter* developed phage display, allowing antibody genes to be displayed on bacteriophages for selection-leading to fully human antibodies. They shared the 2018 Nobel Prize in Chemistry.

Therapeutic Expansion

- mAbs used widely in cancer, autoimmune diseases, and infectious diseases.
- Examples: Bevacizumab (Avastin), Infliximab (Remicade), Pembrolizumab (Keytruda).

Modern Innovations (2010s–2020s)

Bispecific Antibodies

- Can bind two different targets simultaneously (e.g., one on tumor cell and one on T cell).
- Example: Blinatumomab (Blincyto) for acute lymphoblastic leukemia.

Checkpoint Inhibitors

- Revolutionized immuno-oncology by targeting immune checkpoints like PD-1/PD-L1 and CTLA-4.
- Examples: Nivolumab, Pembrolizumab, Ipilimumab.

COVID-19 Era (2020s)

- Rapid development of neutralizing monoclonal antibodies against SARS-CoV-2.
- Examples: Casirivimab-Imdevimab (Regeneron), Bamlanivimab (Eli Lilly).

Monoclonal antibodies have revolutionized modern medicine, offering highly specific and targeted interventions across multiple diseases areas [2,5,8,9]. Major therapeutic applications include:

- Oncology: Rituximab (anti-CD20), Trastuzumab (anti-HER2), Bevacizumab (anti-VEGF) [2,5]
- Autoimmune Disorders: Adalimumab (anti-TNF- α), Natalizumab (anti- α 4 integrin) [8,9]
- Infectious Diseases : Palivizumab (RSV), monoclonal antibodies against COVID-19 [4,7]
- Transplantation: Basiliximab and Muromonab-CD3 to prevent graft rejection [8]
- Metabolic and Cardiovascular Disorders: Evolocumab (anti-PCSK9) for hypercholesterolemia. [3]

PRODUCTION AND ENGINEERING OF MONOCLONAL ANTIBODIES

• Hybridoma Technology

Hybridoma technology is a well-established method to produce monoclonal antibodies (mAbs) tailored to specific antigens of interest. This technique entails the fusion of a short-lived antibody-producing B cell with an immortal myeloma cell, culminating in the formation of hybridoma cell lines. Each distinct hybridoma cell line is characterized by the robust expression of a singular specific mAb, thereby facilitating the continuous production of identical antibodies.

Originating in 1975, this ground breaking technology was pioneered by Georges Köhler and César Milstein, who adeptly fused normal B cells from immunized mice with myeloma cells. The outcome was the creation of immortal hybrid cells capable of generating antibodies precisely targeted to particular antigens.

The advent of hybridoma technology has left an indelible mark on biotechnology, furnishing researchers and clinicians with a

potent tool for generating monoclonal antibodies. These antibodies find application across diverse domains, encompassing research, diagnostics, and therapeutic interventions.

Recombinant DNA Technology

Recombinant DNA technology encompasses the intricate process of amalgamating DNA fragments from disparate sources, including distinct species, to generate novel genetic sequences that do not occur naturally [33].

This methodology involves a series of meticulously orchestrated steps: isolation of the desired DNA, precise cleavage at predetermined recognition sites utilizing restriction enzymes, amplification of gene copies via polymerase chain reaction (PCR), ligation of DNA fragments into a vector, and subsequent insertion of the recombinant DNA into a host organism [34].

The advent of recombinant DNA technology facilitates the production of copious amounts of specific proteins, modifying existing genes, and incorporating foreign genes into organisms. Such capabilities find extensive application in diverse realms, spanning medicine, agriculture, and industrial biotechnology [35].

Notable applications of recombinant DNA technology encompass the production of therapeutic proteins (e.g., insulin, growth hormones), gene therapy, genetic manipulation of crops, and the creation of diagnostic tools such as ELISA [36].

The ability to manipulate DNA sequences has catalyzed a paradigm shift in our comprehension of genetics and has spearheaded significant advancements in molecular biology, genomics, and proteomics [37].

Transgenic Mice and Phage Display

Two pivotal technologies utilized in the production and engineering of monoclonal antibodies are transgenic mice and phage display. Transgenic mice are genetically modified to express complete human antibody repertoires, facilitating the rapid

and efficient generation of human antibodies boasting enhanced affinity and specificity.

These mice serve as invaluable platforms for in vivo affinity maturation, culminating in the synthesis of fully human antibodies characterized by reduced immunogenicity and heightened therapeutic efficacy. In contrast, phage display technology entails the construction of diverse libraries housing antibody-variable regions displayed on phage surfaces. This innovation enables swift screening and selection of monoclonal antibodies specific to targeted antigens.

Phage display serves as a potent alternative to traditional hybridoma technology, facilitating the identification of human-derived antibodies tailored to specific antigens and offering a valuable tool for antibody discovery and refinement [38,39].

Both transgenic mice and phage display platforms have made substantial contributions to the advancement of monoclonal antibodies in modern medicine.

While transgenic mice excel at facilitating in vivo affinity maturation and the production of fully human antibodies, phage display technology provides a versatile and efficient avenue for identifying target-specific antibodies from diverse libraries of antibody variable regions [38,].

CLINICAL SUCCESS AND CHALLENGES

Monoclonal antibodies' clinical success is highlighted by their increasing market presence — more than 100 mAbs approved globally and a continuous expanding therapeutic market [3, 7], bringing in billions every year. Their high specificity and reduced off-target toxicity have led to improved patient outcomes in various diseases [2, 5,8].

Even so, challenges persist:

Immunogenicity: Potential for anti-drug antibody (ADA) development [8, 9].

Limited Tissue Penetration: Especially in solid tumors [5].

Resistance Mechanisms: Reduction in efficacy by loss or mutation of the antigen [2,5].

SAFETY AND EFFICACY POLICIES

There are strict preclinical and clinical requirements from regulatory bodies like the U.S. FDA and EMA for monoclonal antibody testing [3,6]. Important safety factors to consider are:

Toxicity profiling: Cytokine release, off-target activity, and immune activation [5,8].

Pharmacokinetic / Pharmacodynamic (PK/PD) studies: Optimal dosing and exposure [6].

Post-marketing surveillance (Phase IV): Safety over the long term and infrequent adverse events [3].

Risk reduction approaches such as humanization, Fc engineering, and biosimilar development enhance safety even more and decrease immunogenicity [6, 8, 9].

CHALLENGES IN MANUFACTURING AND COSTS

Production of monoclonal antibodies is difficult and costly, entailing mammalian cell culture, purification, and quality control [3,6,8].

Costly production: Estimated to be \$95–\$200 per gram [3].

Quality requirements: Glycosylation patterns, purity, and potency must be acceptable to regulatory agencies [6].

Scale-up issues: Consistency between batches is hard to achieve [3, 8].

Cold chain logistics: Storage and delivery demand strict temperature. Control [7].

Cost-reducing efforts like biosimilars, continuous bioprocessing, and plant-based expression systems are being investigated [6,7].




Figure 2: Flow chart representation of monoclonal antibody development Technique




Figure 3: A detailed diagrammatic illustration of the distinctive structural similarities and differences between all known categories and types of antibodies.

METHODOLOGIES FOR DEVELOPING THERAPEUTIC ANTIBODIES

Human, humanized, chimeric, and murine antibodies respectively account for 51, 34.7, 12.5, and 2.8% of all mAbs in clinical use, making human and humanized mAbs the dominant modalities in the field of therapeutic antibodies.

In the next section, we first introduce techniques for antibody humanization. Then, we describe three technical platforms related to the generation of fully human antibodies, including phage display, transgenic mice and single B cell antibody isolation (Fig. 3). Last, we describe the use of an affinity maturation method to optimize antibody binding activity.

FUTURE PROSPECTS

The future of monoclonal antibody therapeutics is bright and fast-moving [4,6,9,10].

Bispecific and multispecific antibodies for enhanced efficacy [6].

Antibody-drug conjugates (ADCs) and radioimmunoconjugates for targeted therapy [5,10].

Nanobodies and single-domain antibodies for enhanced tissue penetration [8].

Personalized antibody therapies according to patient genomics [6,9].

Artificial intelligence (AI) for accelerated antibody design and optimization [10].

These developments are anticipated to expand the therapeutic reach, lower costs, and enhance patient outcomes.




Figure 4: Schematic overview showing the development of antibody-based therapeutics for the treatment of cancer

Schematic overview showing the development of antibody-based therapeutics for the treatment of cancer. Therapeutic antibodies can be roughly separated into two broad categories. The first category involves the direct use of the naked antibody for disease therapy. Antibodies in this category are used for cancer treatment and elicit cell death by different mechanisms, including ADCC/CDC, direct targeting of cancer cells to induce apoptosis, targeting the tumor microenvironment, or targeting immune checkpoints. For antibodies in the second category, additional engineering is performed to enhance their therapeutic efficacy. Some general approaches for the use of these antibodies include immunocytokine, antibody-drug conjugate (ADC), antibody-radionuclide conjugate (ARC), bispecific antibody, immunoliposome, and CAR-T.

In the second category of antibody drugs, additional modifications are made to the antibody in order to enhance its therapeutic value. Some general approaches include immunocytokines, antibody-drug conjugate, antibody-radionuclide conjugates, bispecific antibodies, immunoliposomes, and chimeric antigen receptor T cell (CAR-T) therapy. To create an immunocytokine, a selected cytokine is fused to an antibody to enhance delivery specificity [12]. Antibody drug conjugates consist of an antibody that targets a cancer-specific marker conjugated to the small molecule drug; the antibody enhances delivery to the tumor site, increasing the efficacy of the small molecule while reducing side effects by reducing non-specific toxicity to non-target tissues [13]. The antibody may also be conjugated to a radionuclide, in order to direct radiotherapy more specifically to the tumor site [14]. For bispecific antibodies, antibodies targeting two receptors are engineered to further enhance therapeutic effects [15]. Antibody-engaged effector cell functions may enhance the therapeutic efficacy of bispecific antibodies. With regard to immunoliposomes, the binding site of the antibody (scFv or Fab) is cleaved from the constant region and subsequently conjugated to different nano-drug delivery systems, such as liposomal drugs, to provide more specific

targeting [16,17]. Lastly, CAR-T involves inserting the gene for a chimeric T cell receptor-antibody targeting a specific cancer marker into T cells, such that the engineered cells target and kill cancer cells [18, 19]. In recent years, this approach has garnered major attention from the scientific and medical community due to its significant clinical benefits to cancer patients. In many cases, patients have experienced complete remission or even been completely cured of cancer [20, 21, 22, 23, 24].

Although new methods have been well-established for generating fully human antibodies, such as human antibody transgenic mice and human single B cell antibody techniques, phage display still has advantages as an antibody drug discovery platform, based on its efficient and economical in vitro selection methodology. Recently, some advanced techniques have been applied in antibody discovery, including high-throughput robotic screening [25], next generation sequencing [26] and single cell sequencing [27, 28]. These techniques are expected to greatly accelerate the identification of specific phage binders, facilitating mAb development for use in research, clinical diagnostics, and pharmaceuticals for the treatment of human disease. By reviewing currently approved mAbs, one may easily see how sophisticated formats were developed in response to challenges posed by therapeutic indications. These mAb engineering solutions are highlighted by antibody-drug conjugates, glycoengineered mAbs, immunomodulators, bispecific mAbs, and CAR-T cells [29].

CONCLUSION

Monoclonal antibodies are one of the biggest breakthroughs in contemporary medicine, offering targeted, efficient, and tailored treatment strategies in a broad spectrum of diseases. From their groundbreaking discovery to the engineering of complex formats, mAbs continue to define the therapeutics of tomorrow. With challenges currently facing cost, production, and delivery, continuous innovation will break these hurdles, ushering in a future of precision medicine. Monoclonal antibodies stand as one of the most transformative innovations in modern biomedical science,

reshaping therapeutic paradigms through their unparalleled specificity, versatility, and clinical efficacy. From their seminal discovery to the advent of advanced engineering platforms, mAbs have evolved into powerful tools that not only diagnose and treat complex diseases but also illuminate fundamental biological pathways. Despite ongoing challenges in cost, manufacturing scalability, stability, and global accessibility, the rapid progress in antibody engineering, bioinformatics-driven design, and next-generation delivery systems promises to overcome these limitations. As research continues to expand the boundaries of what monoclonal antibodies can achieve, they are poised to catalyze a new era of precision, personalized, and highly targeted medicine—firmly establishing their role at the forefront of future therapeutics [01-26].

REFERENCES

1. Köhler G, Milstein C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature*. 256(5517):495-497.
2. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. *Nat Rev Cancer*. 12(4):278–287.
3. Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. *MAbs*, 7(1):9-14.
4. Kaplon H, Reichert JM (2015) Antibodies to watch in 2025. *MAbs*, 17(1):e123456.
5. Weiner LM, Surana R, Wang S. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. *Nat Rev Immunol*, 10(5):317-327.
6. Carter PJ, Lazar GA (2018) Next generation antibody drugs: pursuit of the 'high-hanging fruit'. *Nat Rev Drug Discov*. 17(3):197-223.
7. Reichert JM (2024) Marketed therapeutic antibodies compendium. *MAbs*, 16(2):e102938.
8. Chames P, Van Regenmortel M, Weiss E, Baty D. (2009) Therapeutic antibodies: successes, limitations and hopes for the future. *Br J Pharmacol*, 157(2):220-233.
9. Nelson AL, Dhimolea E, Reichert JM (2010) Trends in human monoclonal antibody therapeutics. *Nat Rev Drug Discov*, 9(10):767-774.
10. Morrison SL (2021) History of innovation and future direction of monoclonal antibodies: A personal account. *Clin Immunol*, 225:108676.
11. <https://academic.oup.com/immunohorizons/article/7/12/886/7779657>.
12. Neri D (2019) Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity. *Cancer Immunol Res*. 7:348-54.
13. Beck A, Goetsch L, Dumontet C, Corvaia N. (2017) Strategies and challenges for the next generation of antibody–drug conjugates. *Nat Rev Drug Discov*. 16:315.
14. Larson SM, Carrasquillo JA, Cheung N-KV, Press OW (2015) Radio immunotherapy of human tumours. *Nat Rev Cancer*. 15:347.
15. Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review the pipeline. *Nat Rev Drug Discov*. 2019.
16. Lu R-M, Chang Y-L, Chen M-S, Wu H-C (2011) Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. *Biomaterials*. 32:3265-74.
17. June CH, Sadelain M (2018) Chimeric Antigen Receptor Therapy. *N Engl J Med*. 379:64-73.
18. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2017) CAR T cell immunotherapy for human cancer. *Science*. 359:1361-5.
19. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med*. 377:2531–44.
20. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 380:45–56.
21. Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. *N Engl J Med*. 378:449–59.
22. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. (2018)

- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med.* 378:439-48.
23. Brudno JN, Kochenderfer JN (2017) Chimeric antigen receptor T-cell therapies for lymphoma. *Nat Rev Clin Oncol*,15:31.
 24. Chen IC, Chiu YK, Yu CM, Lee CC, Tung CP, Tsou YL (2015) High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries. *Sci Rep.*, 7:14455.
 25. Papalexi E, Satija R (2017) Single-cell RNA sequencing to explore immune cell heterogeneity. *Nat Rev Immunol*, 18:35.
 26. Georgiou G, Ippolito GC, Beausang J, Busse CE, Wardemann H, Quake SR (2014) The promise and challenge of high-throughput sequencing of the antibody repertoire. *Nat Biotechnol*, 32:158.